Shares of Celyad SA (NASDAQ:CYAD) have received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating. Celyad SA’s rating score has improved by 50% from three months ago as a result of a number of analysts’ ratings changes.

Brokers have set a one year consensus target price of $49.00 for the company, according to Zacks. Zacks has also given Celyad SA an industry rank of 104 out of 265 based on the ratings given to related companies.

A number of equities analysts have commented on CYAD shares. BidaskClub lowered Celyad SA from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. ValuEngine raised Celyad SA from a “sell” rating to a “hold” rating in a research note on Thursday, June 29th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $49.00 price objective (up previously from $35.00) on shares of Celyad SA in a research note on Friday, September 1st.

A hedge fund recently raised its stake in Celyad SA stock. Victory Capital Management Inc. grew its holdings in Celyad SA (NASDAQ:CYAD) by 6.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 374,493 shares of the company’s stock after purchasing an additional 22,600 shares during the quarter. Victory Capital Management Inc. owned about 3.93% of Celyad SA worth $9,988,000 as of its most recent filing with the SEC. 4.06% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at

Celyad SA (NASDAQ:CYAD) opened at 52.26 on Friday. The firm’s market capitalization is $495.58 million. Celyad SA has a one year low of $16.31 and a one year high of $52.50. The stock’s 50 day moving average price is $41.36 and its 200-day moving average price is $35.97.

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Get a free copy of the Zacks research report on Celyad SA (CYAD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with's FREE daily email newsletter.